INFLUENCE OF FOOD ON THE BIOAVAILABILITY OF A SUSTAINED-RELEASE VERAPAMIL PREPARATION

被引:11
作者
CONWAY, EL [1 ]
PHILLIPS, PA [1 ]
DRUMMER, OH [1 ]
LOUIS, WJ [1 ]
机构
[1] UNIV MELBOURNE,AUSTIN HOSP,DEPT MED,CLIN PHARMACOL & THERAPEUT UNIT,HEIDELBERG,VIC 3084,AUSTRALIA
关键词
D O I
10.1002/jps.2600790310
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The effects of food on the bioavailability of a sustained‐release (SR) formulation of verapamil (SR‐verapamil; Isoptin SR) were determined in an open, three‐way single‐dose study involving 12 volunteers receiving (in randomized order) the SR preparation (1 × 240 mg) either fasting or with food and a conventional formulation of verapamil (3 × 80 mg) fasting. Compared with the conventional formulation, SR‐verapamil had a reduced Cmax, prolonged tmax, and unchanged t1/2, consistent with its SR formulation. The AUC was 80% of the conventional preparation. Concomitant food administration significantly prolonged the tmax of SR‐verapamil from 7.3 ± 3.4 to 11.7 ± 6.3 h, but had little effect on Cmax, t1/2, or AUC. Similar results were obtained with the metabolite, norverapamil. Food administration also had little effect on the blood pressure and ECG effects of SR‐verapamil. Cautions regarding taking this preparation with food therefore appear to be unnecessary. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:228 / 231
页数:4
相关论文
共 15 条
[1]   EFFECTS OF D,1-VERAPAMIL ON ATRIOVENTRICULAR-CONDUCTION IN RELATION TO ITS STEREOSELECTIVE 1ST-PASS METABOLISM [J].
ECHIZEN, H ;
VOGELGESANG, B ;
EICHELBAUM, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (01) :71-76
[2]   CLINICAL PHARMACOKINETICS OF VERAPAMIL, NIFEDIPINE AND DILTIAZEM [J].
ECHIZEN, H ;
EICHELBAUM, M .
CLINICAL PHARMACOKINETICS, 1986, 11 (06) :425-449
[3]   PHARMACOKINETICS OF (+)-VERAPAMIL, (-)-VERAPAMIL AND (+/-)-VERAPAMIL AFTER INTRAVENOUS ADMINISTRATION [J].
EICHELBAUM, M ;
MIKUS, G ;
VOGELGESANG, B .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 17 (04) :453-458
[4]  
EICHELBAUM M, 1979, DRUG METAB DISPOS, V7, P145
[5]   PHARMACOKINETICS OF CONVENTIONAL AND SLOW-RELEASE VERAPAMIL [J].
FOLLATH, F ;
HA, HR ;
SCHUTZ, E ;
BUHLER, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 :S149-S153
[6]   CLINICAL PHARMACOKINETICS OF VERAPAMIL [J].
HAMANN, SR ;
BLOUIN, RA ;
MCALLISTER, RG .
CLINICAL PHARMACOKINETICS, 1984, 9 (01) :26-41
[7]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF VERAPAMIL .2. SIMULTANEOUS QUANTITATION OF VERAPAMIL AND ITS ACTIVE METABOLITE, NORVERAPAMIL [J].
HARAPAT, SR ;
KATES, RE .
JOURNAL OF CHROMATOGRAPHY, 1980, 181 (3-4) :484-489
[8]   PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 FORMULATIONS OF VERAPAMIL [J].
HLA, KK ;
HENRY, JA ;
LATHAM, AN .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 24 (05) :661-664
[9]   INFLUENCE OF FOOD-INTAKE ON PRESYSTEMIC CLEARANCE OF DRUGS [J].
MELANDER, A ;
MCLEAN, A .
CLINICAL PHARMACOKINETICS, 1983, 8 (04) :286-296
[10]   INFLUENCE OF FOOD ON BIOAVAILABILITY OF DRUGS [J].
MELANDER, A .
CLINICAL PHARMACOKINETICS, 1978, 3 (05) :337-351